DPD 3 tablets

Hazard statements (CLP)

H372

Code

Statements

H372

Causes damage to organs through prolonged or repeated exposure

SECTION 2: Hazards identification

According to Regulation (EC) No. 1272/2008 (CLP) Classification of the substance or mixture

Adverse physicochemical, human health and environmental effects

To our knowledge, this product does not present any particular risk, provided it is handled in accordance with good occupational hygiene and safety practice

Hazard pictograms

GHS08

Signal word

Danger

Contains

POTASSIUM IODIDE

Hazard statements

H372 - Causes damage to organs through prolonged or repeated exposure.

Precautionary statements

P264 - Wash hands, forearms and face thoroughly after handling. P314 - Get medical advice/attention if you feel unwell.

Other hazards which do not result in classification

The main intake pathways of potassium iodide are: inhalation of dust and solution aerosols, as well as oral ingestion. Contains no PBT and/or vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or substance(s) are not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %

2.1 Classification of the substance or mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP] Specific target organ toxicity – Repeated exposure, Category 1 H372 Full text of H- and EUH-statements: see section 16 Adverse physicochemical, human health and environmental effects To our knowledge, this product does not present any particular risk, provided it is handled in accordance with good occupational hygiene and safety practice.